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AbstrACt
Introduction How to provide practice-integrated decision 
support to patients remains a challenge. We are testing 
the effectiveness of a practice-integrated programme 
targeting patients with a physician recommendation for 
colorectal cancer (CRC) screening.
Methods and analysis In partnership with healthcare 
teams, we developed ‘e-assist: Colon Health’, a patient-
targeted, postvisit CRC screening decision support 
programme. The programme is housed within an 
electronic health record (EHR)-embedded patient portal. 
It leverages a physician screening recommendation 
as the cue to action and uses the portal to enrol and 
intervene with patients. Programme content complements 
patient–physician discussions by encouraging screening, 
addressing common questions and assisting with barrier 
removal. For evaluation, we are using a randomised trial in 
which patients are randomised to receive e-assist: Colon 
Health or one of two controls (usual care plus or usual 
care). Trial participants are average-risk, aged 50–75 
years, due for CRC screening and received a physician 
order for stool testing or colonoscopy. Effectiveness will 
be evaluated by comparing screening use, as documented 
in the EHR, between trial enrollees in the e-assist: Colon 
Health and usual care plus (CRC screening information 
receipt) groups. Secondary outcomes include patient-
perceived benefits of, barriers to and support for CRC 
screening and patient-reported CRC screening intent. 
The usual care group will be used to estimate screening 
use without intervention and programme impact at the 
population level. Differences in outcomes by study arm will 
be estimated with hierarchical logit models where patients 
are nested within physicians.
Ethics and dissemination All trial aspects have been 
approved by the Institutional Review Board of the health 
system in which the trial is being conducted. We will 
disseminate findings in diverse scientific venues and will 
target clinical and quality improvement audiences via other 
venues. The intervention could serve as a model for filling 
the gap between physician recommendations and patient 
action.
trial registration number NCT02798224; Pre-results.
IntroduCtIon 
Despite the availability of multiple effective 
colorectal cancer (CRC) screening tests, CRC 
screening remains underused relative to other 
cancer screening tests.1 We have found that 
a driving factor behind this underutilisation 
for insured individuals is the gap that exists 
between physician recommendation and 
patient receipt of care. We previously found 
strengths and limitations of this study
 ► Trial addresses how electronic health record (EHR)-
embedded, online decision support and assistance 
can be used following patients’ receipt of physician 
order for colorectal cancer (CRC) screening.
 ► Use of EHR-embedded patient portal to enrol pa-
tients and deliver intervention facilitates practice 
integration and provides efficient and sustainable 
platform for intervention.
 ► Programme facilitates informed decision making 
and addresses common barriers to and questions 
regarding CRC screening, thereby filling known gaps 
in office visit discussions.
 ► Enrolling and intervening with patients via the pa-
tient portal limits the programme’s reach to those 
already engaged with portal technology.
 ► Study findings may be limited in that they may not 
generalise to other settings.
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that while the overwhelming majority (93%) of insured 
people due for CRC screening when visiting a physician 
office received a recommendation for screening, only 
54% were screened in the following year.2 Despite the 
known importance of physician recommendations to 
CRC screening use,3 4 the gap between recommendation 
and screening use, in part, may be explained by the poor 
quality of typical patient–physician CRC screening discus-
sions that have been shown to fall short of recommended 
decision-making processes and omit addressing common 
patient questions and CRC screening barriers.3 5 6 To 
address these shortfalls, and close the gap between physi-
cian recommendation and care receipt, interventions are 
needed that encourage patient follow through, address 
lingering patient questions and assist with barrier removal 
following a physician recommendation for screening.
How to offer such decision support and assistance to 
patients in a way that is practice integrated remains a chal-
lenge. Individual health navigators hold promise, espe-
cially for low literacy patients, but costs associated with 
such programmes limit scalability.7 8 Patient reminders and 
the removal of structural barriers can increase screening 
use, but these techniques leave many unscreened and are 
disconnected from physician recommendations and other 
existing clinic processes.7 9–19 Similarly, traditional decision 
aids provided before an office visit often result in improved 
patient knowledge, but limited (if any) changes in screening 
behaviours and have proven difficult to integrate within 
practice.20–23 The effectiveness of such previously tested 
CRC screening programmes may be limited by a combina-
tion of factors. These include their failure to be practice inte-
grated and thus capitalise on the powerful patient–physician 
relationship and cue to action that exists once a physician 
recommends CRC screening, and the missed opportunity to 
intervene after an office visit in which CRC has been recom-
mended with programme content that is complementary to 
typical office-based CRC screening discussions.
By leveraging the platform of an online patient 
portal that is embedded within the electronic health 
record (EHR), we have developed a practice-integrated, 
patient-targeted CRC screening programme, e-assist: 
Colon Health. The programme is delivered to patients 
via an EHR-embedded patient portal after an office visit 
in which CRC screening has been recommended, thereby 
leveraging physician recommendations as a cue to action. 
Programme content reinforces screening benefits and 
addresses typical patient questions and the personal and 
structural barriers faced once a physician recommenda-
tion has been received. We are evaluating e-assist: Colon 
Health using a practice-embedded trial in which patients 
are randomised to receive e-assist: Colon Health or one of 
two control arms (usual care plus or usual care).
Aims and hypotheses
The primary outcome of interest for the randomised trial 
is receipt of EHR-documented CRC screening within 12 
months of physician recommendation. The overall aims 
of the evaluation include:
Aim 1: to compare screening use, intent to screen and 
patient perceptions among trial enrollees receiving e-as-
sist: Colon Health and usual care plus.
H1: a larger proportion of trial enrollees receiving 
e-assist: Colon Health, compared with trial enrollees 
receiving usual care plus, will be screened for CRC within 
12 months of receiving the physician recommendation.
H2: a larger proportion of trial enrollees receiving e-as-
sist: Colon Health, compared with enrollees receiving 
usual care plus, will report intending to be screened at 
the time of the follow-up survey.
H3: trial enrollees receiving e-assist: Colon Health 
will perceive more benefits from CRC screening, more 
screening support and fewer CRC screening barriers at 
the time of the follow-up survey as compared with trial 
enrollees receiving usual care plus.
Aim 2: to evaluate whether the effectiveness of e-assist: 
Colon Health is moderated by factors including patient 
health literacy, decision-making preference and CRC 
screening decision stage as reported by trial enrollees at 
baseline.
H4: the effectiveness of e-assist: Colon Health will be 
greater among patients with low health literacy (compared 
with those with high health literacy), a preference for less 
directed decision making (compared with those with a 
preference for directed decision making) and a low deci-
sion stage (compared with those with a higher decision 
stage).
Aim 3: to characterise the impact of e-assist: Colon 
Health at a primary care population level by describing 
the ability of the programme to reach the target popu-
lation and by comparing CRC screening use across the 
three study arms.
MEthods
Conceptual framework
Intervention and trial design are guided by the Health 
Belief Model (HBM),24 the Precaution Adoption Process 
Model and Self-Determination Theory.25–28 The HBM 
suggests that people’s use of preventive services is 
explained by their perceived threat of disease, benefits 
of the service, barriers to and self-efficacy for obtaining 
screening. The model also acknowledges the need for a 
stimulus, or cue to action, to trigger the behaviour. The 
HBM provides overarching guidance for intervention 
design (eg, provision of information regarding the risks 
and consequences of CRC, and the benefits of screening; 
offering assistance overcoming barriers to screening; and 
addressing structural barriers to completing screening by 
providing direct access to stool testing and assistance with 
completing screening) as well as the impetus for targeting 
patients immediately following a primary care visit with 
an order for CRC screening (ie, an external cue to action 
that has occurred within established clinic processes). 
The HBM, however, does not provide guidance on how 
to personalise health communications and other inter-
vention components to maximise message salience and 
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accompanying action. The Precaution Adoption Process 
Model provides this guidance by building on the core 
elements of the HBM and considering how a person 
comes to decisions to take action.26 Specifically, the indi-
vidual’s readiness to engage in the healthful behaviour is 
based on their ‘decision stage’. The premise behind the 
model is that different factors influence different stage 
transitions and that messages can be strategically designed 
to move individuals through the stages.29 30 For example, 
the e-assist: Colon Health programme offers patients who 
indicate they are not ready to be screened suggestions for 
how to overcome common personal barriers to screening. 
Likewise, patients who indicate they are undecided about 
how to be screened are provided with information about 
the pros and cons of different test options, while those 
indicating they are ready to be screened are provided 
with tips for completing their preferred screening test 
and assistance removing structural barriers that may arise. 
Finally, we use principles from Self-Determination Theory 
to guide the tone of the written messages and ensure they 
are autonomy supporting28 and are not overly directive 
or controlling. For example, the programme provides 
information on other types of CRC screening tests only 
to those who express an interest in this information and 
then emphasises that modality choice is up to the patient.
study setting
The trial is being conducted within the primary care 
practice of an integrated health system. The practice’s 
33 primary care clinics are located throughout the city 
of Detroit and the surrounding suburban tricounty area. 
Clinics are staffed by approximately 150 salaried, adult 
primary care (ie, general internal medicine and family 
medicine) physicians. The health system uses a commer-
cial EHR that includes an embedded patient portal.31
Patient and public involvement
The design of the programme and its integration with 
clinic workflow and practice were achieved via continual 
partnerships with care delivery and support teams. The 
user-centred design was used to ensure programme 
acceptability, scalability and sustainability. Patient input 
via focus groups, in-depth interviews and beta testing was 
used to develop the content of the e-assist: Colon Health 
programme.32
study design
We are evaluating the e-assist: Colon Health programme 
using a three-arm, randomised trial. The trial is pragmatic 
and practice embedded, in that it uses available EHR data 
to identify, recruit and follow-up eligible patients.33 34 By 
embedding these processes within the health system’s 
infrastructure, we are able to invite a broad, generalisable 
group of patients and to do so in an efficient and sustain-
able way should the intervention be found effective under 
such ‘real world’ conditions.
To be consistent with the health system’s preventive 
health practices, the inclusion and exclusion criteria for 
the trial was guided by the US Preventive Services Task 
Force guidelines for CRC screening.35 As such, aver-
age-risk patients, aged 50–75 years, due for CRC screening 
were randomised to receive: (1) an online patient portal 
message with links to the interactive e-assist: Colon Health 
programme (experimental treatment); (2) an online 
patient portal message with links to Healthwise CRC and 
CRC screening educational material (usual care plus)36; 
or (3) usual care. For the effectiveness evaluation, we will 
use an intent-to-treat analysis among those consenting 
to study participation in the experimental treatment 
and usual care plus arms. Because an outreach commu-
nication specific to CRC screening following a physician 
recommendation may itself serve as a reminder and cue 
to action, we will use the third arm, for which there is 
no outreach communication or consent, to describe 
screening use in a population without any postvisit 
communication about CRC screening (usual care). The 
latter will be used to estimate programme impact at the 
population level. The evaluation framework is depicted 
in figure 1.
Figure 1 Evaluation framework. The figure provides an overview of the implementation and patient outcomes that are being 
assessed as part of the e-assist: Colon Health study. CRC, colorectal cancer. 
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Eligible patient identification and randomisation
Because of the desire to automate the workflow to 
recruit and intervene with patients and the inability to 
conduct randomisation within the EHR environment, 
we randomised all potentially trial-eligible patients before 
opening the trial to enrolment. This was done by using 
the EHR data repository to identify patients who would 
become study eligible if they were to receive a physician 
recommendation for CRC screening during the trial 
enrolment period. This list of potentially trial-eligible 
participants was generated by identifying average-risk 
men and women aged 50–75 years who were due for CRC 
screening as recommended by the US Preventive Services 
Task Force Guidelines,35 had an activated online patient 
portal account and per administrative records were 
assigned to a primary care physician practising in one 
of the health system’s 33 primary care clinics. Patients 
with EHR-documented colonoscopy in the past 10 years, 
sigmoidoscopy in the past 5 years or faecal occult blood 
test (FOBT) or faecal immunochemical test (FIT) in the 
past 12 months were excluded as were patients known to 
be above average risk for CRC (ie, those with a personal or 
family history of CRC, those with prior polyps or a history 
of inflammatory bowel disease, familial adenomatous 
polyposis or hereditary non-polyposis). Patients without 
an activated portal account and who were not aligned to 
a primary care physician were also excluded.
SAS software V.9.4 was used to randomly allocate poten-
tially trial-eligible patients to the experimental treat-
ment, usual care plus or usual care study arms. To ensure 
adequate sample size for the primary effectiveness analyses 
that will compare CRC screening use between the experi-
mental treatment and the usual care plus groups (both of 
which require patient consent), we used a 2:2:1 ratio for 
randomisation. The pool of potentially eligible patients is 
scheduled to be updated approximately annually.
study enrolment and baseline assessment
Figure 2 outlines the study processes from the identifica-
tion of potentially trial-eligible patients through outcome 
measurement. As indicated in figure 2, while the trial is 
open for enrolment, the list of potentially trial-eligible 
participants (as identified above) is monitored electron-
ically and continuously to identify those with an ambula-
tory care visit to a primary care physician that includes 
a referral for an open access colonoscopy, an order for 
stool testing (ie, FOBT or FIT), or both. Once a poten-
tially eligible patient receives such an order, they become 
trial eligible. When the physician closes the encounter (ie, 
visit note within the EHR), if the patient has a preassigned 
randomisation code reflective of either the experimental 
treatment or usual care plus group, a secure message is 
sent automatically to the patient’s online portal account 
inviting them to access an attached link that contains 
the decision support intervention appropriate to their 
study arm. Once an eligible patient opens the attached 
link, they are invited to participate in the study. Those 
continuing past an online consent page are considered 
enrolled in the trial. Trial enrolment is continuing until 
900 patients are enrolled in each of the two study arms 
requiring consent (ie, the experimental treatment and 
usual care plus). At that time, any individual who was 
randomised to usual care and received a primary care 
physician order for CRC screening will be included in the 
usual care arm.
Figure 3 provides an overview of the study contact 
procedures by study arm as well as a brief synopsis of the 
intervention content (the latter of which is described in 
more detail below). For those in the experimental treat-
ment and usual care plus groups, the online programmes 
contain a brief baseline questionnaire consisting of 
six measures that are being collected to assess balance 
between the experimental treatment and active compar-
ison study arms and to enable the testing of patient-level 
factors that may moderate the effectiveness of e-assist: 
Colon Health. As indicated in table 1, these include 
previously validated measures of health literacy37 and 
measures adapted for CRC screening such as perceived 
worry,38 decision-making preference,39–41 perceived 
susceptibility,42 43 screening history44 and CRC screening 
decision-making stage.45 No similar assessment is given to 
the usual care group.
outcome measures and follow-up assessment
As indicated in table 1, the primary effectiveness outcome 
for the trial is a binary variable reflecting CRC screening 
use in the 12-month period following the date of physi-
cian recommendation. Screening use is being deter-
mined by an EHR-documented occurrence of any of the 
following: colonoscopy, flexible sigmoidoscopy, FOBT, 
FIT or stool DNA testing. Patients for whom no indication 
of testing is identified in the EHR will be assumed not to 
have received screening.
Secondary outcomes include patient-perceived bene-
fits of,46 barriers to and support for CRC screening and 
patient-reported CRC screening intent (table 1).47–49 The 
latter of which is obtained using a measure of behavioural 
intent adapted for CRC screening.45 These secondary 
outcomes are being assessed via a telephone survey 
administered to participants enrolled in the experimental 
treatment and usual care plus arms only. The telephone 
survey is being administered 4–8 weeks following trial 
enrolment.
Experimental treatment: e-assist: Colon health
The e-assist: Colon Health programme is designed to 
serve as an online visit extender, filling known voids in 
typical office-based CRC screening decision-making 
processes and addressing key personal and structural 
barriers to CRC screening once a physician order has 
been placed. Programme content includes images, newly 
developed text and seven videos that were developed in 
the context of another NCI-funded trial (NCT01885351). 
After consenting to study participation and answering the 
baseline questionnaire, patients randomised to receive 
e-assist: Colon Health are able to view the content of the 
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initial module. There are five central components to the 
initial module: (1) messaging and a video to reiterate that 
CRC screening is recommended; (2) messaging to provide 
information on different screening modalities and associ-
ated benefits/risks; (3) a screening test option compar-
ison to assist patients in determining their screening test 
preference; (4) messaging and videos addressing ways to 
overcome common personal barriers to screening; and 
(5) messaging to assist with completing screening once 
a decision to screen has been made. The majority (89%) 
of e-assist: Colon Health text content assesses at or below 
a sixth grade reading level with the remainder (11%) at 
a seventh grade level, as evaluated by the Flesch-Kincaid 
Grade Level test.50
Although messaging regarding the benefits of CRC 
screening and testing guidelines are seen by everyone, 
Figure 2 Study processes. The figure identifies how patients were identified, randomised, recruited and followed during the 
e-assist: Colon Health study. CRC, colorectal cancer; EHR, electronic health record. 
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much of the programme’s content is self-directed, 
enabling users to choose the material they want to view 
and the order in which they view it. Patients’ readi-
ness to screen along with their informational and CRC 
screening preferences are assessed through questions 
embedded throughout the programme. Participant 
responses are used to tailor the programme content seen 
to the participants’ decision stage and preferences. The 
specific assistance a patient receives (eg, instructions for 
how to schedule a colonoscopy; instructions for how to 
prepare for a colonoscopy screening; requesting mailed 
delivery of stool test; or instructions for how to complete 
stool test) is similarly tailored based on the participant’s 
responses to embedded questions. What participants view 
and the order in which they view it are being tracked as 
part of the implementation effectiveness component of 
Figure 3 Intervention content and contact procedures by study arm. The figure summarises the points and content of 
participant contact during the e-assist: Colon Health study. CRC, colorectal cancer; EHR, electronic health record. 
Table 1 Measures and schedule of measurement for trial participants receiving e-assist: Colon Health or the usual care plus
Measure
Baseline
questionnaire
Follow- up
survey*
Medical record 
documented†
Primary outcome CRC screening X
Secondary outcomes CRC screening intent45 X
Barriers to CRC screening47 48 X
CRC screening benefits46 X
Patient-provider
supportive
communication49
X
Moderating factors Health literacy37 X X
CRC Decision Stage45 X
Decision-making preference39–41 X X
Perceived worry38 X X
CRC screening history44 X
Perceived CRC susceptibility42 43 X X
*Follow-up survey administered 4–8 weeks following for trial enrolment.
†CRC screening as indicated by receipt of colonoscopy, flexible sigmoidoscopy, faecal occult blood testing, faecal immunochemical testing 
or stool DNA testing within 12 months of physician recommendation for screening as documented in the electronic health record.
CRC, colorectal cancer.
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the evaluation. Although participants can return to the 
initial module as often as they want until they submit it 
as completed, we anticipate most participants completing 
the initial module in one session that lasts between 8 
min and 12 min, depending up information viewed.
Near the end of the initial module, a course of action 
is negotiated that is aligned with the patient’s preferences 
and willingness to be screened. If a participant’s responses 
indicate he or she is ready to be screened, the e-assist: 
Colon Health programme facilitates receipt of screening 
by assisting with the removal of structural barriers that 
may arise (eg, how to call the endoscopy nurse schedulers 
with questions). For participants expressing a desire to be 
screened using a test different from what their physician 
ordered, the programme assists in obtaining their desired 
CRC screening test by providing contact information for 
the central scheduling line or messaging the patient’s 
physician directly.
Any participant that does not indicate they have 
completed CRC screening when they submit their initial 
module receives a follow-up module. Much of the content 
in this follow-up is similar to that available in the initial 
module although targeted based on the information and 
preferences shared via question responses within the 
initial module. For example, if during the first module 
a participant elected to send a secure message to their 
primary care physician requesting a stool test, the content 
in the follow-up module would confirm that the partici-
pant received the stool test and offer tips for completion. 
For patients that do not express a desire to be screened, 
the follow-up module presents information using a moti-
vational counselling approach.51 This approach is aimed 
at moving patients who are undecided or not consid-
ering screening towards a concrete decision. It does so 
by highlighting the personal relevance of screening, the 
risks of CRC and the benefits of screening, while identi-
fying personally relevant barriers. There are a total of 11 
different follow-up modules. As with the initial module, 
programme navigation within each of these modules is 
self-directed with participants’ responses to embedded 
questions used to tailor the programme content seen. All 
follow-up modules are delivered 2 weeks after the initial 
module was submitted as completed, with the exception 
of those targeting participants who indicated they were 
not ready to be screened or those who abandoned the 
programme without submitting it. For the former, the 
follow-up module is sent 28 days later, while for the latter, 
7 days later.
usual care plus
Patients randomised to usual care plus receive the iden-
tical recruitment message as those in the experimental 
arm (figure 3). Also identical are the consent form page 
and introductory screens reiterating that CRC screening 
has been recommended for them and outlining the 
benefits of screening. In lieu of the interactive e-assist: 
Colon Health programme, individuals in usual care plus 
receive links to four webpages, one of which contains a 
video, that are stored within the patient portal’s health 
information library. The educational material is currently 
distributed by Healthwise and includes information on 
the aetiology, symptoms and treatment of CRC as well as 
screening modalities and the interpretation of screening 
results.36 With the exception of the one video, all material 
is static, and none is individually tailored.
Similar to participants in the experimental treatment 
group, participants enrolled in usual care plus are sent 
a follow-up module. The reminder module, which is 
also not tailored, is sent 2 weeks after the initial module. 
It includes a welcome screen and a link to the National 
Cancer Institute’s CRC screening website.52 This webpage 
provides patients with information on CRC screening 
and serves as a comparable alternative to the Healthwise 
information initially provided to the usual care plus. This 
allows the usual care plus group to run parallel to the 
experimental treatment in both timing as well as breadth 
of content provided (figure 3).
usual care
Patients randomised to usual care receive CRC screening 
information and instructions as routinely provided by the 
health system. While the same Healthwise material that 
is being pushed to patients enrolled in usual care plus 
is available to these participants via the health library 
accessible within the EHR, unlike in usual care plus, 
participants are not being systematically directed to this 
material. Thus, while patients in this arm, by virtue of 
their portal account, have access to the same Health-
wise material on CRC and CRC screening, access to the 
library containing these documents is not readily identi-
fiable within the portal. Similarly, those materials could 
be printed for patients at the time of an office visit, but to 
our knowledge, this rarely, if ever, happens.
Analysis plan
The primary outcome for the evaluation is a binary vari-
able (EHR-documented CRC screening use within 12 
months as defined above), which will be available regard-
less of treatment assignment or consent status. Secondary 
outcomes, all measured at the time of the follow-up survey, 
are ordinal categorical (eg, screening intent and benefits) 
or continuous (eg, barriers and screening support) and 
available among consenters only, regardless of treatment 
assignment. Each outcome Y will be conditional on treat-
ment assignment T and consent C (the interaction terms 
of), which will identify four groups: consenters (C=1) and 
non-consenters (C=0) assigned to treatment (T=1) and 
usual care plus or control (T=0). 
For the effectiveness evaluation (H1), differences in 
CRC screening between experimental treatment and 
usual care plus will be estimated by a hierarchical logit 
model where patients who consented are nested within 
physicians. Because we will obtain CRC screening use 
data from the EHR with the absence of screening data 
coded as ‘no screening’, there will not be known missing 
values for the primary outcome. For a limited number 
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of trial participants (who, for whatever reason, elect to 
receive screening elsewhere), this may result in unknown 
missing values. While this will represent a trial limitation, 
we do not have reason to expect this missingness to differ 
by study arm.
For secondary outcomes (H2 and H3), we will use hier-
archical generalised linear models and hierarchical linear 
models to analyse categorical and continuous outcomes, 
respectively, where patients who consented are nested 
within physicians.53 We will compare the treatment effects 
for consenters, moderated by patient characteristics, to 
test H4 for aim 2. For H2–H4, we will handle missing data 
from survey item non-responses and unit non-responses 
efficiently by analysing all observed data.54–56
For the impact evaluation, we will compare screening 
rates across the three trial arms for consenters and 
non-consenters by a hierarchical logit model, analysing 
the entire sample. The effects of consenters will be 
compared with each other and those of non-consenters to 
describe the population represented by the experiment. 
We will also analyse a hierarchical model for the consent 
outcome C, which will describe who the beneficiaries of 
the treatment and usual care plus are in terms of their 
characteristics. One difficulty is that each patient in the 
usual care arm is missing the consent status. That is, if the 
patient was assigned to the other arms, he or she would 
have or would not have consented to study participation. 
We will view missing consent as missing data and estimate 
the hierarchical models by efficient handling of missing 
data, that is, by all observed data.54–58
Power and sample size calculations
To account for the clustering of patients nested within 
physicians, statistical power for the primary effectiveness 
evaluation (ie, the comparison of outcomes between 
the experimental treatment and usual care plus) was 
estimated using an R program written by Dr Jessaca 
Spybrook implementing the method in Spybrook and 
Hedberg, and Moerbeek et al.59 60 With randomisation 
at the patient level, we consider a 95% plausible interval 
for CRC screening use in the experimental treatment 
(66%±5%) at alpha=0.05 in the usual care plus arm. With 
1800 patients seen by 150 primary care physicians, or 12 
patients per physician (6 in the experimental treatment 
and 6 in the usual care plus), we have 0.86 power to 
detect a 7% change in CRC screening rates between the 
experimental treatment and the usual care plus (ie, 66% 
vs 59%, respectively).
trial status
As indicated in figure 2, prior to opening trial enrolment, 
19 085 patients were identified as potentially eligible and 
randomised (7752 to the experimental treatment, 7626 to 
usual care plus and 3707 to usual care). The trial opened 
for enrolment at 13:00 eastern standard time on 14 June 
2017 with recruitment planned to end in early 2019. 
Seven months into trial recruitment (14 January 2018), 
2175 of the potentially eligible patients have received a 
primary care physician order for CRC screening (1110 
in the experimental group and 1065 in the usual care 
plus group). This has resulted in n=328 patients being 
enrolled in the experimental group and n=376 in the 
usual care plus group. We have identified two barriers to 
trial enrolment among those receiving a physician order 
for CRC screening, and thus an invitation for trial partici-
pation. First, approximately 30% of patients who are sent 
an email notification that they have a new portal message 
never log into their portal account to read the message. 
In addition, among patients who log into their portal 
account and read the message, about 50% elect not to 
open the attachment that includes information on the 
trial (eg, consent information) and the decision support 
programmes. We are currently using in-depth interviews 
with patients who elected not to log into their portal 
account or not to open the attachment to gain insights 
into other means by which to engage such patients with 
decision support following physician recommendations 
for care.
Ethics and dissemination plan
The Institutional Review Board (IRB) approved the 
trial under an expedited review and, given the benefit/
risk ratio, waived the need for written patient consent. 
A Health Insurance Portability and Accountability Act 
(HIPAA) waiver of authorisation was received to enable 
the inclusion of the usual care group. The trial is funded 
by the National Cancer Institute (7R01CA197205).
Findings, whether positive or negative, will enable clini-
cians and other healthcare stakeholders to make informed 
decisions about how to integrate new portal technology 
to support primary care patients in their decision making 
and service receipt. We will disseminate emerging stories, 
lessons learnt and findings on an ongoing basis. Manu-
scripts and presentations will be prepared for publication 
in diverse scientific venues, and we will target brief reports 
and presentations for the clinical, quality improvement 
and EHR communities as well as make use of emerging 
online repositories.
Data requests can be submitted to the corresponding 
author at the UNC Eshelman School of Pharmacy, Univer-
sity of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina, after conclusion of the trial and publication of 
the primary manuscript.
dIsCussIon
To our knowledge, this is the first trial to test an online prac-
tice-integrated, postvisit CRC screening decision support 
programme that does not rely on direct human resources 
to help patients address lingering questions about CRC 
screening and overcome personal and structural barriers to 
screening use once a physician recommendation is in hand. 
As such, we are testing an intervention that fills an important 
gap in clinical care that has yet to be addressed. Our trial and 
programme are unique in their use of clinical workflow-in-
tegrated automation. By automating patient identification 
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and programme delivery, we are facilitating programme 
sustainability should e-assist: Colon Health succeed. By inter-
vening with patients following a regularly scheduled office 
visit in which they received a physician recommendation 
for CRC screening, we are able to use a naturally occur-
ring clinical event as the cue for patient action, thereby 
capitalising on the known powerful relationships between 
patients and their physicians. By using the patient portal 
to do so, we are ensuring that e-assist: Colon Health is fully 
integrated within existing clinic processes. The e-assist: 
Colon Health programme will extend, in a personalised and 
autonomy-supporting manner, the patient–physician CRC 
screening decision-making process beyond the confines of 
office visits. Thus, unlike traditional decision aids adminis-
tered prior to a visit, we do not anticipate that e-assist: Colon 
Health will alter the patient–physician office visit interaction 
per se; instead we expect e-assist: Colon Health to extend the 
patient’s ability to consider CRC screening in a supportive 
setting postreceipt of physician recommendation and to 
improve the patient’s perception of the autonomy support 
they receive from their doctor’s office. The fact that the 
programme is accessed via an existing patient portal furthers 
its integration with increasingly common clinic processes, 
streamlines patient accessibility and begins to address prior 
challenges of implementation faced by previous decision aid 
studies.
Recent reviews indicate that, compared with usual care, 
people who use decision aids benefit from improved knowl-
edge, a better understanding of their values and enhanced 
participation in the decision-making process.23 61 62 Despite 
the known benefits of decision aid use, physicians voice 
concerns regarding their practicality and,22 63 to date, their 
integration within practice is limited.21 22 Our trial, via our 
ongoing engagement with clinician and other healthcare 
stakeholders, is illustrating how these barriers can be over-
come. The challenge is that while communication outreach 
strategies embedded within a patient portal may be sustain-
able and acceptable to healthcare stakeholders, they engage 
only a small subset of the patient population.64 Furthermore, 
there is increasing evidence that use of a portal among 
those with an account varies, with patients from tradition-
ally disadvantaged publications being relatively less engaged 
even once they have a portal account.65 66 Our trial and 
its decision support intervention appears to be no excep-
tion. Thus, an overarching limitation of the trial is that its 
reach is limited to those already engaged with the portal. 
Prior studies have repeatedly shown this to be a relatively 
small segment of the population, and one in which minori-
ties and other traditionally disadvantaged populations are 
under-represented.67–76 In addition, our trial is limited by its 
implementation and recruitment within one health system 
that may further limit the ability to generalise results.
Facilitating the timely use of CRC screening among primary 
care patients requires that scalable programmes be designed 
to address barriers to obtaining a physician recommenda-
tion for care and the quality of that recommendation and 
the personal and system barriers faced once patients have a 
physician recommendation for care. Identifying sustainable 
strategies to support patient adherence to evidence-based 
care is critical for patient-centred medical homes and other 
delivery settings if we are to effectively and efficiently deliver 
preventive health services. Supporting patient adherence to 
known effective preventive health services is also critical to 
the ability to reduce the morbidity and mortality associated 
with preventable diseases such as CRC.
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